Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women

Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women

Background: The therapeutic targeting of PD-1/PD-L1 has shown clinical efficacy in treating metastatic breast cancer. We investigated the clinical significance of measuring serum PD-L1 levels in African-American and Hispanic women with breast cancer. Methods: PD-L1 levels were measured with the ELIS...

Full description

Bibliographic Details
Main Authors:	Yanyuan Wu, Pranabananda Dutta, Sheilah Clayton, Amaya McCloud, Jaydutt V. Vadgama
Format:	Article
Language:	English
Published:	MDPI AG 2022-01-01
Series:	Journal of Clinical Medicine
Subjects:	PD-L1 TNBC survival CD44 PTEN
Online Access:	https://www.mdpi.com/2077-0383/11/2/283

Similar Items

Transcriptional Regulation of <i>CCL2</i> by PARP1 Is a Driver for Invasiveness in Breast Cancer
by: Pranabananda Dutta, et al.
Published: (2020-05-01)

Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women
by: Yanyuan Wu, et al.
Published: (2017-10-01)

PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
by: Daniele Cretella, et al.
Published: (2019-09-01)

PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
by: Duaa Alkaabi, et al.
Published: (2023-03-01)

Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
by: Joe Yeong, et al.
Published: (2019-02-01)

Prognostic Significance of PD-L1 and PTEN Expression in Prostatic Cancer
by: Noha Elaidy, et al.
Published: (2022-04-01)

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
by: Sunny Kumar, et al.
Published: (2023-07-01)

Inflammatory Cytokines Associated with Obesity, Type-2 Diabetes, and Hypertension Exacerbate Breast Cancer Risk in Underserved African American and Latin American Women
by: Yanyuan Wu, et al.
Published: (2024-03-01)

Correction: Dutta et al. Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer. <i>Cancers</i> 2020, <i>12</i>, 1317
by: Pranabananda Dutta, et al.
Published: (2023-12-01)

Palladium-Spermine Complex (Pd<sub>2</sub>Spm) Triggers Autophagy and Caspase-Independent Cell Death in Triple-Negative Breast Cancer Cells
by: Martin Vojtek, et al.
Published: (2022-11-01)

PTEN Expression Was Significantly Associated with PD-L1 Score but Not with EBV Infection in Gastric Cancer
by: Cao D, et al.
Published: (2022-09-01)

SHP2 potentiates anti-PD-1 effectiveness through intervening cell pyroptosis resistance in triple-negative breast cancer
by: Chao Chen, et al.
Published: (2023-12-01)

PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment—A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters
by: Olga Stanowska, et al.
Published: (2022-09-01)

Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization Against PARP1 Inhibition in a Replication-Dependent Manner
by: Johanna Rieckhoff, et al.
Published: (2020-09-01)

Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer
by: Hsuan‐Chen Liu, et al.
Published: (2023-11-01)

Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer
by: Martin J. Raftery, et al.
Published: (2023-05-01)

Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.
by: Yanyuan Wu, et al.
Published: (2013-01-01)

RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer
by: Huijie Yang, et al.
Published: (2022-12-01)

Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1
by: Hongpei Tan, et al.
Published: (2023-07-01)

The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer
by: Yanlin Bian, et al.
Published: (2022-07-01)

Synthesis and Biological Evaluation of (<i>S</i>)-2-(Substituted arylmethyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-<i>a</i>]indole-3-carboxamide Analogs and Their Synergistic Effect against PTEN-Deficient MDA-MB-468 Cells
by: Ye-Mi Kwon, et al.
Published: (2021-09-01)

Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC
by: Cinzia Vetrei, et al.
Published: (2021-12-01)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
by: Rosa Rapuano Lembo, et al.
Published: (2022-10-01)

Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1
by: Nishant Mohan, et al.
Published: (2022-06-01)

PTEN Dual Lipid- and Protein-Phosphatase Function in Tumor Progression
by: Anne Liu, et al.
Published: (2022-07-01)

Enhanced Chemoprevention of Prostate Cancer by Combining Arctigenin with Green Tea and Quercetin in Prostate-Specific Phosphatase and Tensin Homolog Knockout Mice
by: Qiongyu Hao, et al.
Published: (2024-01-01)

Combination of AAV-delivered tumor suppressor PTEN with anti-PD-1 loaded depot gel for enhanced antitumor immunity
by: Yongshun Zhang, et al.
Published: (2024-01-01)

BAT26 Only Microsatellite Instability with High Tumor Mutation Burden—A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression
by: So Young Kang, et al.
Published: (2022-09-01)

Effect of CTP-mediated PTEN on 5637 bladder cancer cells and the underlying molecular mechanism
by: Bei Yu, et al.
Published: (2022-12-01)

Roles of Protein Disulfide Isomerase in Breast Cancer
by: Suhui Yang, et al.
Published: (2022-01-01)

Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells
by: Simona Camorani, et al.
Published: (2022-10-01)

Imunoterapia no cancro de mama triplo-negativo: o papel dos inibidores de checkpoint imunológico
by: Susana Branco, et al.
Published: (2022-11-01)

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group
by: Mieke R. Van Bockstal, et al.
Published: (2021-09-01)

RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis
by: Hao Zhang, et al.
Published: (2023-01-01)

PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers
by: Kholoud Alwosaibai, et al.
Published: (2023-01-01)

Mace‐Like Plasmonic Au‐Pd Heterostructures Boost Near‐Infrared Photoimmunotherapy
by: Yanlin Feng, et al.
Published: (2023-02-01)

PTEN Protein Loss and Loss-of-Function Mutations in Gastric Cancers: The Relationship with Microsatellite Instability, EBV, HER2, and PD-L1 Expression
by: Binnari Kim, et al.
Published: (2020-06-01)

Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma
by: Catia Giovannini, et al.
Published: (2023-03-01)

Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancer
by: Huihui Li, et al.
Published: (2023-01-01)

Nuclear PTEN’s Functions in Suppressing Tumorigenesis: Implications for Rare Cancers
by: Casey G. Langdon
Published: (2023-01-01)